Thomas Taapken 

  •                                 
    Extbase Variable Dump
    'distribution:BiomSpeaker.html' (29 chars)
    
                            
  •                                     
    Extbase Variable Dump
    'fileadmin/Webdata/Uploads/Veranstaltungen/2025/BayOConnect_2025/Speaker/Taap
     ken_300x300.jpg    ' (91 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Thomas Taapken' (14 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'CFO, InflaRx' (12 chars)
    
                                
  •                                     
    Extbase Variable Dump
    'Thomas joined lnflaRx as CFO in 2020. He has over 25 years of experience in 
     senior management positions within the life sciences sector and as a venture
      investor. He has previously held positions as CFO of Medigene AG (publicly 
     listed in Germany), as CEO and CFO of Epigenomics AG (publicly listed in Ger
     many), where he led the company's efforts in gaining regulatory approval for
      the company's lead product with the FDA and oversaw its subsequent introduc
     tion into the US market, and as CFO at Biotie Therapies (Turku, Finland) and
      its predecessor companies. Before that he was a venture investor for 7 year
     s with Deutsche Venture Capital (DVC) and Burrill & Co. in the US. Thomas st
     arted his career at Hoechst AG (now Sanofi). He holds a Ph.D. in organic che
     mistry from the Technical University of Berlin and also studied economics, c
     hemistry and physics at the University of Göttingen. Thomas is a Board membe
     r of Scibase AB since 2017, he was Chairman of the Board at lmcyse SA from J
     une 2019 until May 2024.    ' (1012 chars)